HER2-negative patients include those with triple-negative breast cancer (oestrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative), which is associated with an aggressive disease course and particularly poor outcomes.6 This evidence concerns the gene PGR and triple-negative breast carcinoma.